首页> 外文OA文献 >Lithocholic Acid Is an Eph-ephrin Ligand Interfering with Eph-kinase Activation
【2h】

Lithocholic Acid Is an Eph-ephrin Ligand Interfering with Eph-kinase Activation

机译:胆酸是一种麻黄配体,会干扰麻黄激酶 激活

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Eph-ephrin system plays a central role in a large variety of human cancers. In fact, alterated expression and/or de-regulated function of Eph-ephrin system promotes tumorigenesis and development of a more aggressive and metastatic tumour phenotype. In particular EphA2 upregulation is correlated with tumour stage and progression and the expression of EphA2 in non-trasformed cells induces malignant transformation and confers tumorigenic potential. Based on these evidences our aim was to identify small molecules able to modulate EphA2-ephrinA1 activity through an ELISA-based binding screening. We identified lithocholic acid (LCA) as a competitive and reversible ligand inhibiting EphA2-ephrinA1 interaction (Ki = 49 µM). Since each ephrin binds many Eph receptors, also LCA does not discriminate between different Eph-ephrin binding suggesting an interaction with a highly conserved region of Eph receptor family. Structurally related bile acids neither inhibited Eph-ephrin binding nor affected Eph phosphorylation. Conversely, LCA inhibited EphA2 phosphorylation induced by ephrinA1-Fc in PC3 and HT29 human prostate and colon adenocarcinoma cell lines (IC50 = 48 and 66 µM, respectively) without affecting cell viability or other receptor tyrosine-kinase (EGFR, VEGFR, IGFR1β, IRKβ) activity. LCA did not inhibit the enzymatic kinase activity of EphA2 at 100 µM (LANCE method) confirming to target the Eph-ephrin protein-protein interaction. Finally, LCA inhibited cell rounding and retraction induced by EphA2 activation in PC3 cells. In conclusion, our findings identified a hit compound useful for the development of molecules targeting ephrin system. Moreover, as ephrin signalling is a key player in the intestinal cell renewal, our work could provide an interesting starting point for further investigations about the role of LCA in the intestinal homeostasis.
机译:eph-ephrin系统在多种人类癌症中发挥着核心作用。实际上,Eph-ephrin系统表达的改变和/或功能的失调促进了肿瘤的发生和更具侵略性和转移性的肿瘤表型的发展。特别地,EphA2的上调与肿瘤的阶段和进展相关,并且在非转化细胞中EphA2的表达诱导恶性转化并赋予致瘤潜力。基于这些证据,我们的目的是通过基于ELISA的结合筛选鉴定能够调节EphA2-ephrinA1活性的小分子。我们确定了石胆酸(LCA)是一种竞争性且可逆的配体,可抑制EphA2-ephrinA1相互作用(Ki = 49 µM)。由于每种ephrin均结合许多Eph受体,因此LCA也无法区分不同的Eph-ephrin结合,表明与Eph受体家族的高度保守区域相互作用。结构相关的胆汁酸既不抑制Eph-ephrin结合,也不影响Eph磷酸化。相反,LCA抑制了ephrinA1-Fc在PC3和HT29人前列腺和结肠腺癌细胞系(分别为IC50 = 48和66 µM)中诱导的EphA2磷酸化,而不影响细胞活力或其他受体酪氨酸激酶(EGFR,VEGFR,IGFR1β,IRKβ) )活动。 LCA在100 µM(LANCE方法)下不抑制EphA2的酶促激酶活性,从而证实了靶向Eph-ephrin蛋白-蛋白相互作用。最后,LCA抑制了PC3细胞中EphA2激活诱导的细胞变圆和收缩。总而言之,我们的发现确定了一种对开发针对ephrin系统的分子有用的命中化合物。此外,由于ephrin信号传导是肠道细胞更新的关键因素,因此我们的工作可能为进一步研究LCA在肠道稳态中的作用提供有趣的起点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号